Abstract
61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 114-115 |
| Number of pages | 2 |
| Journal | Clinical nuclear medicine |
| Volume | 42 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2017 |
Keywords
- IMLYGIC
- PET
- T-VEC
- immunotherapy
- in-transit metastasis
- melanoma
- talimogene laherparepvec
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS